News

Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
MarketWatch21h
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. Barbara ...
Fierce Pharma17h
Consumers remain averse to out-of-pocket GLP-1 costs: KPMG
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
Zacks Investment Research on MSN9h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Connecticut Public12h
Most people eligible for injectable weight loss drugs in the US can't get them, Yale study finds
Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...